Compare MCO & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCO | BSX |
|---|---|---|
| Founded | 1900 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.7B | 93.4B |
| IPO Year | 1998 | 2010 |
| Metric | MCO | BSX |
|---|---|---|
| Price | $448.19 | $63.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 21 |
| Target Price | ★ $542.06 | $102.10 |
| AVG Volume (30 Days) | 932.5K | ★ 14.5M |
| Earning Date | 04-22-2026 | 04-22-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | 21.40 | ★ 55.20 |
| EPS | ★ 13.67 | 1.94 |
| Revenue | $4,204,100,000.00 | ★ $9,076,000,000.00 |
| Revenue This Year | $8.51 | $11.91 |
| Revenue Next Year | $7.76 | $10.26 |
| P/E Ratio | ★ $32.73 | $33.29 |
| Revenue Growth | N/A | ★ 12.49 |
| 52 Week Low | $402.28 | $60.59 |
| 52 Week High | $546.88 | $109.50 |
| Indicator | MCO | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 38.72 |
| Support Level | $422.18 | $60.59 |
| Resistance Level | $450.66 | $76.77 |
| Average True Range (ATR) | 10.99 | 1.80 |
| MACD | 2.27 | 0.46 |
| Stochastic Oscillator | 78.37 | 29.82 |
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed-income securities. The ratings segment, Moody's Investors Service, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's profit and often (depending on bond issuance levels) a majority of the firm's revenue. The other segment, Moody's Analytics, consists of decision solutions, research and insights, and data and information.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.